We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in our Benign Hematology. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Benign Hematology

Journal Scan / Research · December 02, 2022

Role of Venetoclax Plus Hypomethylating Agents in Higher-Risk Myelodysplastic Syndrome

Blood Cancer Journal

 

Additional Info

Blood Cancer Journal
Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome
Blood Cancer J 2022 Nov 04;12(11)148, RS Komrokji, AM Singh, NA Ali, O Chan, E Padron, K Sweet, A Kuykendall, JE Lancet, DA Sallman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading